LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$718.50 |
52 Week High | US$737.00 |
52 Week Low | US$309.90 |
Beta | 0.34 |
1 Month Change | 1.20% |
3 Month Change | 36.60% |
1 Year Change | 130.25% |
3 Year Change | 355.38% |
5 Year Change | 519.02% |
Change since IPO | 1,164.10% |
Recent News & Updates
Recent updates
Shareholder Returns
LLY | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 1.6% | 2.3% | 1.9% |
1Y | 130.3% | -25.9% | 7.3% |
Return vs Industry: LLY exceeded the German Pharmaceuticals industry which returned -25.9% over the past year.
Return vs Market: LLY exceeded the German Market which returned 7.3% over the past year.
Price Volatility
LLY volatility | |
---|---|
LLY Average Weekly Movement | 4.1% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LLY's share price has been volatile over the past 3 months.
Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | https://www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
LLY fundamental statistics | |
---|---|
Market cap | €644.75b |
Earnings (TTM) | €4.84b |
Revenue (TTM) | €31.52b |
133.8x
P/E Ratio20.5x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LLY income statement (TTM) | |
---|---|
Revenue | US$34.12b |
Cost of Revenue | US$7.08b |
Gross Profit | US$27.04b |
Other Expenses | US$21.80b |
Earnings | US$5.24b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 5.82 |
Gross Margin | 79.25% |
Net Profit Margin | 15.36% |
Debt/Equity Ratio | 233.4% |
How did LLY perform over the long term?
See historical performance and comparison